SETD2和EZH2:两个前列腺癌的表观遗传驱动因素
Jiamin Wang1, Longquan Xiang2, Haiyan Zhang3
1School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.
Journal of Cancer
|September 17, 2025
概括
前列腺癌的进展涉及表观遗传调节剂SETD2和EZH2. 针对这个SETD2/EZH2轴为新的精确疗法提供了针对晚期前列腺癌的潜力.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 前列腺癌转移和治疗耐药性是复杂的,受到表观遗传修饰的影响.
- 基隆甲基转移酶SETD2和EZH2是前列腺癌进展的关键调节剂.
- SETD2的损失与侵入性相关,而EZH2的过度表达促进了转移和治疗抵抗.
研究的目的:
- 系统地审查前列腺癌中SETD2/EZH2轴的分子机制.
- 为开发针对前列腺癌表观遗传修饰的精密疗法提供基础.
主要方法:
- 综合综述多主题研究和临床前数据.
- 分析涉及SETD2,EZH2和相关途径的分子机制.
- 检查治疗策略,包括表观遗传抑制剂和组合疗法.
主要成果:
- SETD2损失促进了侵入性和上皮层-介质细胞过渡.
- 过度表达EZH2驱动转移和抵抗割的前列腺癌,通常与PI3K-AKT信号合作.
- SETD2直接调节EZH2的稳定性,形成一个协调的表观遗传轴.
- SETD2抑制剂 (例如,EZM0414) 和EZH2抑制剂 (例如,tazemetostat) 显示出临床前的抗瘤活性,但面临抗药性.
结论:
- SETD2/EZH2轴是前列腺癌进展和治疗耐药性的关键调节器.
- 通过表观遗传疗法准这一轴,可能与免疫疗法结合,对精准医学具有前景.
- 需要进一步的研究来克服耐药性和瘤微环境异质性,以提高临床疗效.
更多相关视频
10:26Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
8.8K
10:38Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
Published on: November 22, 2019
9.5K
相关概念视频
Epigenetic Regulation
3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.7K
Epigenetic Regulation
33.5K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.5K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.6K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.6K
Master Transcription Regulators
7.7K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.7K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
